News Column

Findings from Y.N. Abdiche and Co-Authors Update Knowledge of Immunoglobulins

June 18, 2014

By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Immunology are discussed in a new report. According to news reporting out of South San Francisco, California, by NewsRx editors, research stated, "Here, we demonstrate how array-based label-free biosensors can be applied to the multiplexed interaction analysis of large panels of analyte/ligand pairs, such as the epitope binning of monoclonal antibodies (mAbs). In this application, the larger the number of mAbs that are analyzed for cross-blocking in a pairwise and combinatorial manner against their specific antigen, the higher the probability of discriminating their epitopes."

Our news journalists obtained a quote from the research, "Since cross-blocking of two mAbs is necessary but not sufficient for them to bind an identical epitope, high-resolution epitope binning analysis determined by high-throughput experiments can enable the identification of mAbs with similar but unique epitopes. We demonstrate that a mAb's epitope and functional activity are correlated, thereby strengthening the relevance of epitope binning data to the discovery of therapeutic mAbs. We evaluated two state-of-the-art label-free biosensors that enable the parallel analysis of 96 unique analyte/ligand interactions and nearly ten thousand total interactions per unattended run. The IBIS-MX96 is a microarray-based surface plasmon resonance imager (SPRi) integrated with continuous flow microspotting technology whereas the Octet-HTX is equipped with disposable fiber optic sensors that use biolayer interferometry (BLI) detection. We compared their throughput, versatility, ease of sample preparation, and sample consumption in the context of epitope binning assays. We conclude that the main advantages of the SPRi technology are its exceptionally low sample consumption, facile sample preparation, and unparalleled unattended throughput. In contrast, the BLI technology is highly flexible because it allows for the simultaneous interaction analysis of 96 independent analyte/ligand pairs, ad hoc sensor replacement and on-line reloading of an analyte-or ligand-array."

According to the news editors, the research concluded: "Thus, the complementary use of these two platforms can expedite applications that are relevant to the discovery of therapeutic mAbs, depending upon the sample availability, and the number and diversity of the interactions being studied."

For more information on this research see: High-throughput epitope binning assays on label-free array-based biosensors can yield exquisite epitope discrimination that facilitates the selection of monoclonal antibodies with functional activity. Plos One, 2014;9(3):e92451. (Public Library of Science -; Plos One -

Our news journalists report that additional information may be obtained by contacting Y.N. Abdiche, Rinat-Pfizer Inc, South San Francisco, California, United States. Additional authors for this research include A. Miles, J. Eckman, D. Foletti, T.J. Van Blarcom, Y.A. Yeung, J. Pons and A. Rajpal (see also Immunology).

Keywords for this news article include: California, Biosensing, Immunology, United States, Bioengineering, Blood Proteins, Immunoglobulins, Serum Globulins, Bionanotechnology, Nanobiotechnology, South San Francisco, Monoclonal Antibodies, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters